Health data security and patient engagement are top priorities for the nation's hospitals, according to results of the 17th annual HealthCare's Most Wired Survey. The annual survey was released by the American Hospital Association's Health Forum and the College of Healthcare Information Management Executives (CHIME).
St. Jude Medical, Inc. announced the launch of the ILUMIEN III clinical trial on June 30. ILUMIEN III is a prospective, international, randomized trial evaluating the clinical benefits of the company's optical coherence tomography (OCT) guidance during stent implantation. The study will compare OCT-guided stent implantation to implantation guided by intravascular ultrasound (IVUS) or angiography alone, diagnostic tools that offer less resolution than OCT during intravascular assessments and percutaneous coronary intervention (PCI).
During an event with Massachusetts Gov. Charlie Baker in June, Abiomed announced a major expansion of its U.S. headquarters in Danvers, Massachusetts, and the creation of approximately 100 new, local jobs.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
Mercom Capital Group llc, a global communications and research firm, released its report on funding and mergers and acquisitions (M&A) activity for the Healthcare Information Technology (IT)/Digital Health sector for the second quarter of 2015. The comprehensive report covers deals of all sizes across the globe.
Sorin S.p.A. and Cyberonics Inc. unveiled LivaNova as the name of their combined company, effective at the close of their proposed merger.
The Society for Heart Attack Prevention and Eradication (SHAPE) submitted a letter to the U.S. Preventive Services Task Force (USPSTF) strongly supporting the use of coronary artery calcium to assess an individual's risk of heart attack.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
C.R. Bard Inc. announced the publication of results from the LEVANT 2 study in the June 24, 2015, online issue of The New England Journal of Medicine. Results from LEVANT 2 demonstrated superior primary patency for the Lutonix 035 drug coated balloon percutaneous transluminal angioplasty (PTA) catheter over standard PTA, as well as safety consistent with standard PTA balloons. The Lutonix 035 DCB is an angioplasty balloon coated with a therapeutic dose of the drug paclitaxel, and also utilizes standard mechanical dilatation of the vessel to restore blood flow for patients with peripheral arterial disease (PAD) in the femoropopliteal arteries.
Masimo announced the CE Mark and full market release of MightySat Rx fingertip pulse oximeter for clinical use in CE countries. The device uses Masimo’s SET Measure-Through Motion and Low Perfusion pulse oximetry.
Biosense Webster Inc. announced the launch of the Confidense Module, an innovative technology that streamlines the creation of real-time 3-D maps of a patient’s cardiac structures during catheter ablation procedures. Utilizing an advanced, proprietary algorithm, the module enhances the process for validating information, or “points,” acquired during multi-electrode mapping, enabling electrophysiologists to focus their time and expertise on the most relevant data during the mapping process.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
A new document from the American Society of Echocardiography (ASE) provides detailed guidance for clinicians on how to use echocardiography to see the full picture of the condition of patients with hypertension. The paper, Recommendations on the Use of Echocardiography in Adult Hypertension: A Report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE) is a joint project between ASE and the European Association of Cardiovascular Imaging (EACVI) and will appear in the July issue of the Journal of the American Society of Echocardiography (JASE).
Results from an interim analysis of the Phase III RE-VERSE AD patient study demonstrate that 5 g of idarucizumab immediately reversed the anticoagulant effect of dabigatran (Pradaxa) in patients requiring urgent anticoagulant reversal. No safety concerns relating to idarucizumab were identified. The results have been simultaneously published in the New England Journal of Medicine (NEJM) and presented at the International Society of Thrombosis and Haemostasis 2015 Congress in Toronto, Canada.
Safety accidents drive up costs, damage reputations and lower patient satisfaction scores. For instance, if a patient falls off a system's table after being sedated and is badly injured, it can result in significant repercussions for the provider. This type of scenario is rare, but still causes concern for health systems nationwide.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Here are a few observations on cardiovascular ultrasound advances I made while attending the 2015 American Society of Echocardiography (ASE) annual meeting in June:
DC Devices Inc. announced that it has completed enrollment and implants in the REDUCE LAP-HF trial, an open label, multi-center, single-arm study of the InterAtrial Shunt Device (IASD). The IASD is a transcatheter device for the treatment of diastolic heart failure (DHF), which is also known as heart failure with preserved ejection fraction (HFpEF).
Medraysintell released its updated World Market Report and Directory on Nuclear Medicine, Edition 2015, in late June, providing a description and analysis of the latest developments in nuclear medicine. The 920-page document covers 335 radiopharmaceuticals and radionuclides and 160 companies and institutions active in nuclear medicine.